TABLE 1.
Correlation of PRDM16 expression with clinicopathological characteristics in PTC of the FUSCC cohort.
| Variables | Low (n = 55) | High (n = 55) | P-value | |
| Gender | Female | 46 (56.79%) | 35 (43.21%) | 0.017* |
| Male | 9 (31.03%) | 20 (68.97%) | ||
| Age at diagnosis (years) | <55 | 46 (48.94%) | 48 (51.06%) | 0.589 |
| ≥55 | 9 (56.25%) | 7 (43.75%) | ||
| ETE | Yes | 20 (68.97%) | 9 (31.03%) | 0.017* |
| No | 35 (43.21%) | 46 (56.79%) | ||
| Coexistent HT | Yes | 7 (58.33%) | 5 (41.67%) | 0.541 |
| No | 48 (48.98%) | 50 (51.02%) | ||
| Multifocality | Unifocal | 25 (71.43%) | 10 (28.57%) | 0.002** |
| Multifocal | 30 (40.00%) | 45 (60.00%) | ||
| T stage | T1-T2 | 38 (46.34%) | 44 (53.66%) | 0.189 |
| T3-T4 | 17 (60.71%) | 11 (39.29%) | ||
| LNM | N0&N1a | 34 (42.50%) | 46 (57.50%) | 0.010* |
| N1b | 21 (70.00%) | 9 (30.00%) | ||
| 8th AJCC TNM stage | I-II | 52 (49.50%) | 53 (50.50%) | 0.647 |
| III-IV | 3 (60.00%) | 2 (40.00%) | ||
| 2015 ATA Risk Stratification System Level | Low | 14 (35.90%) | 25 (64.10%) | 0.028* |
| Intermediate & High | 41 (57.75%) | 30 (42.25%) | ||
| BRAFV600E | Wild type | 26 (48.15%) | 28 (51.85%) | 0.703 |
| Mutation | 29 (51.79%) | 27 (48.21%) | ||
| Maximum size of tumor (Mean ± SD, cm) | 1.73 ± 0.81 | 1.41 ± 0.69 | 0.018* | |
*Statistically significant. PRDM16, positive regulatory domain containing 16; PTC, papillary thyroid cancer; FUSCC, Fudan University Shanghai Cancer Center; HT, Hashimoto’s thyroiditis; ETE, extrathyroidal extension; LNM, lymph node metastasis; TNM, tumor–lymph node–metastasis.